First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status.
Scott N. Gettinger
Consultant or Advisory Role - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Frances A. Shepherd
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Scott Joseph Antonia
Consultant or Advisory Role - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Research Funding - MedImmune
Julie R. Brahmer
Consultant or Advisory Role - Bristol-Myers Squibb (U)
Stock Ownership - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Laura Quan Man Chow
Consultant or Advisory Role - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb; University of Washington
Rosalyn A. Juergens
Research Funding - Bristol-Myers Squibb
Hossein Borghaei
Consultant or Advisory Role - Bristol-Myers Squibb; Genentech
Honoraria - Bristol-Myers Squibb; Genentech
Research Funding - Arisaph Pharmaceuticals; Millennium; Pfizer
Yun Shen
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb (B)
Christopher Harbison
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Suresh Alaparthy
Employment or Leadership Position - Bristol-Myers Squibb
Allen C. Chen
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Naiyer A. Rizvi
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb; MedImmune; Roche/Genentech
Research Funding - Arisaph Pharmaceuticals; Millennium; Pfizer